Progress towards an HIV vaccine based on recombinant Bacillus Calmette-Guérin: Failures and challenges

Expert Review of Vaccines

Volumn 5, Issue 6, 2006, Pages 827-838

  Joseph, Joan ^a   Saubi, Narcís ^a   Pezzat, Elías ^b   Gatell, Josep Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Animal model; Cytotoxic T lymphocyte; HIV; HIV immunity; HIV vaccine; Mycobacterium; Recombinant bacillus Calmette Gu rin

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID VECTOR; RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE DRUG DOSE; VACCINE PRODUCTION;

AIDS VACCINES; ANIMALS; BCG VACCINE; HIV ANTIGENS; HIV INFECTIONS; HUMANS; VACCINATION; VACCINES, SYNTHETIC;

EID: 33845898724     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.6.827     Document Type: Review

References (66)

1. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280(5371), 1871-1873 (1998).
2. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68(7), 4650-4655 (1994).
3. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279(5359), 2103-2106 (1998).
4. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181(4), 1365-1372 (1995).
5. Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102(9), 1758-1765 (1998).
6. Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant Vaccines. Nature 351(6326), 456-460 (1991). •• Development of Escherichia coli-mycobacterial shuttle vectors.
7. Melancon-Kaplan J, Hunter SW, McNeil M et al. Immunological significance of Mycobacterium leprae cell walls. Proc. Natl Acad. Sci. USA 85(6), 1917-1921 (1988).
8. Oiso R, Fujiwara N, Yamagami H et al. Mycobacterial Trehalose 6, 6′- dimycolate preferentially induces type 1 helper T cell responses through signal transducer and activator of transcription 4 protein. Microb. Pathol. 39(1-2) 35-43 (2005).
9. Fujita Y, Naka T, Doi T, Yano I. Direct molecular mass determination of trehalose monomycolate from 11 species of mycobacteria by MALDI-TOFF mass spectrometry. Microbiology 151 (Pt 5), 1443-1452 (2005).
10. Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285, 732-736 (1999).
11. Horwitz, MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71, 1672-1679 (2003).
12. Behr, MA BCG-different strains, different vaccines? Lancet Infect. Dis. 2 (2) 86-92 (2002). •• Evolution and differences between Bacillus Calmette-Guérin (BCG) strains.
13. Dennehy M, Williamson AL Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23, 1209-1224 (2005). •• Factors influencing the expression and immune responses to foreign antigens.
14. Lucas S, Nelson AM. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Tuberculosis: Pathogenesis, Protection and Control. Bloom BR (Ed.). Washington, DC, USA, 503-513 (2002).
15. Jacobs WR Jr, Tuckman M, Bloom BR. Introduction of foreign DNA into mycobacteria using a shuttle plasmid. Nature 327(6122), 532-535 (1987).
16. Matsuo K, Yamaguchi R, Yamazaki A et al. Establishment of a foreign antigen secretion system in mycobacteria. Infect. Immun. 58(12), 4049-4054 (1990).
17. Fuerst TR, Stover CK, de la Cruz VF. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol. Ther. 2(1-2), 159-178 (1991).
18. Fuerst TR, de la Cruz VF, Bansal GP, Stover CK. Development and analysis of recombinant BCG vector systems. AIDS Res. Hum. Retroviruses. 8(8), 1451-1455 (1992). • Development of E. coli-mycobacterial shuttle vectors.
19. Dhar N, Rao V, Tyagi AK. Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis. FEMS Microbiol Lett. 190(2), 309-316 (2000). •• Use of different promoters and their effects on the level of expression and immune response induced.
20. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351(6326), 479-482 (1991). • Specific immune response against HIV proteins expressed in recombinant (r)BCG.
21. Winter N, Lagranderie M, Rauzier J et al. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 109(1), 47-54 (1991).
22. Winter N, Lagranderie M Gangloff S et al. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 13(5), 471-478 (1995).
23. Lagranderie M, Murray A Gicquel B et al. Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 11(13), 1283-1290 (1993).
24. Chujoh Y, Matsuo K, Yoshizaki H et al. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B strains by recombinant Mycobacterium bovis BCG-based candidate Vaccine 20, 797-804 (2002).
25. Kanekiyo M, Matsuo K, Hamatake M et al. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis Bacille Calmette-Guérin expressing human immunodeficiency virus Type 1 gag. J. Virol. 79 (14), 8716-8723 (2005). •• Effect of mycobacterial codon optimization on antigen expression and immune response elicited.
26. Cayabyab MJ, Hovav AH, Hsu T et al. Generation of CD8 T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1. Env. J. Virol. 80(4), 1645-1652 (2006). • Effect or BCG pre-existing immunity on recombinant Mycobacterium smegmatis immunization.
27. Yu JS, Peacock JW, Vanleeuwen S et al. Generation of mucosal anti-human immunodeficiency virus Type 1 T cell responses by recombinant Mycobacterium smegmatis. Clin. Vaccine Immunol. 30(11), 1204-1211 (2006).
28. Aravindhan V, Narayanan S, Gautham N et al. Th-2 immunity and CD3+CD45RBlow-activated T cells in mice immunized with recombinant bacillus Calmette-Guerin expressing HIV-1 principal neutralizing determinant epitope. FEMS Immunol. Med. Microbiol. 47, 45-55 (2006).
29. Stover CK, Bansal GP, Hanson MS et al. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178(1), 197-209 (1993).
30. Langermann S, Palaszynski SR, Burlein JE et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 180(6), 2277-2286 (1994).
31. Connell ND, Medina-Acosta E, McMaster WR et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl Acad. Sci. USA 90(24), 11473-11477 (1993).
32. Varaldo PB, Leite LCC, Dias WO et al. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect. Immun. 72(6), 3336-3343 (2004).
33. Pezzat E. Recombinant BCG based HIV development. PhD Thesis. Medicine School. University of Barcelona. June 2005.
34. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6, 951-955 (2000). • Prime-boost vaccination regimens using heterologous vectors.
35. Nkolola JP, Wee EGT, Im EJ et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 11, 1068-1080 (2004).
36. Fennelly GJ, Jacobs WR, Bloom BR. BCG as a recombinant vaccine vector. In: New Generation Vaccines Second Edition. Marcel Dekker, Inc. NY, USA Chapter 28 (1997).
37. Al Zarouni M, Dale JW. Expression of foreign antigens in Mycobacterium bovis BCG strains using different promoters reveals instability of hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis 82(6), 283-291 (2002).
38. Falk, LA, Goldenthal KL, Esparza J et al. Recombinant Bacillus Calmette-Guérin as a potential vector for preventive HIV Type 1 vaccines. AIDS Res. Hum. Retroviruses 16(2), 91-98 (2000).
39. Wada N, Ohara N, Kameoka M et al. Long-lasting immune response induced by recombinant bacillus Calmette-Guerin (BCG) secretion system. Scand. J. Immunol. 43(2), 202-209 (1996).
40. Ami Y, Izumi Y, Matsuo K et al. Priming-boosting vaccination with recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 79(20), 12871-12879 (2005). •• Prime-boost vaccination regimen using rBCG.
41. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10(11), 1240-1244 (2004). • Phase I clinical trial in humans using rBCG in a prime-boost regimen.
42. Honda M, Matsuo K, Nakasone T et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA 92(23), 10693-10697 (1995). •• Use of α-antigen to induce secretion of foreign proteins in rBCG.
43. Lagranderie M, Winter N, Balazuc AM et al. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses. 14(18), 1625-1633 (1998).
44. Yasutomi Y, Koenig S, Haun SS et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150(7), 3101-3107 (1993).
45. Yasutomi Y, Koenig S, Woods RM et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69(4), 2279-2284 (1995). • First protection trial in nonhuman primates model after rBCG immunization.
46. Leung NJ, Aldovini A, Young R, et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env and Nef proteins. Virology 268(1), 94-103 (2000).
47. Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines 3(Suppl. 4), S89-S97 (2004). • Prime-boost vaccination regimen using DNA-rMVA.
48. Goonetilleke NP, McShane H, Hannan CM et al. Enhanced Immunogenicity and protective efficacy against Mycobacterium Tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602-1609 (2003). • Prime-boost vaccination regimen using rBCG and recombinant modified vaccinia virus Ankara in mice.
49. Gheorghiu M, Lagranderie MR, Gicquel BM, Leclerc CD. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun. 62(10), 4287-4295 (1994).
50. Kameoka M, Nishino Y, Matsuo K et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12(2), 153-158 (1994).
51. Rubinstein A, Mizrachi Y, Pettoello-Mantovani M et al. Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J. Acquir. Immune Defic. Syndr.. 22(5), 467-476 (1999).
52. Lallemant-Le Coeur S, Lallemant M, Cheynier D et al. Bacillus Calmette-Guerin immunization in infants born to HIV-1-seropositive mothers. AIDS. 5(2), 195-199 (1991).
53. CDC. BCG Vaccination and Pediatric HIV Infection - Rwanda, 1988-1990. MMWR 40(48) 833-836 (1991).
54. Hesseling AC, Schaaf HS, Hanekom WA et al. Danish bacille Calmette-Guérin vaccine-induced disease in Human Immunodeficency virus-infected children. CID 37 1226-1233 (2003).
55. Pezzat E, Virgili G, Etcheverry F et al. Alpha-antigen promoter from M. Tuberculosis and lysine gene complementation prevent the disruption of heterologous HIV-1 gp120 gene expression by genetic rearrangements in BCG strain lysine auxotrophic. A critical issue for rBCG based HIV vaccine. AIDS vaccine 2004 Conference. Lausanne (Switzerland) (Abstract P225) (2004).
56. Davids V, Hanekom WA, Mansoor N et al. The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants. J. Infect. Dis. 193, 531-536 (2006). • Effect of BCG strain and inoculation route on the induced immune response.
57. Gheorghiu M, Lagrange PH, Lagranderie M et al. The effects of dispersed or surface grown cultures, manufacture and control methods on BCG standardization. Dev. Biol. Stand. 58(A), 191-205 (1986).
58. Lagranderie M, Lo-Man R, Deriaud E et al. Genetic control af antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen Infect. Immun. 65(8), 3057-3064 (1997).
59. Lim EM, Lagranderie M, LeGrand R et al. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res. Hum. Retroviruses 13(18), 1573-1581 (1997).
60. Hiroi T, Goto H, Someya K et al. HIV Mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J. Immunol. 167, 5862-5867 (2001).
61. Kawahara M, Hashimoto A, Toida I, Honda M. Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin. Immunol. 105(3), 326-331 (2002).
62. Kawahara M, Matsuo K, Nakasone T et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen Vaccine 21, 158-166 (2002).
63. Kawahara M, Matsuo K and Honda M. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs Clin. Immunol. 119, 67-78 (2006).
64. Someya K, Cecilia D, Ami Y. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol.. 79(3), 1452-1462 (2005).
65. Mederle I, Le Grand R, Vaslin B et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 21, 4153-4166 (2003).
66. UNAIDS. 2006 report on the global AIDS epidemic: Executive summary. May 2006. Published by UNAIDS. www.unaids.org